Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Incarda Therapeutics Inc.
Headquarters: Newark, CA, United States of America
Website: http://incardatherapeutics.com...
Year Founded: 2009
Status: Private
BioCentury | Dec 11, 2024
Management Tracks
Myles Greenberg named president, CEO of InCarda
Plus: Miguel Fernández Alcalde becomes president of EMD Serono, and updates from CorriXR, Acadia and HealthCare Royalty
BioCentury | May 18, 2023
Management Tracks
Klompas steps down as Zymeworks’ COO, president
Plus: Bloom names Colón chair, Replay hires Balakumaran as CMO
BioCentury | Apr 3, 2023
Management Tracks
Vounatsos, Maraganore to advise Legend
Plus: Kawakami becomes president of Mitsubishi’s U.S. unit and updates from InCarda,
BioCentury | Feb 5, 2022
Discovery & Translation
Wave’s oligos enhance tissue exposure; plus Rosenberg, Disney and more
BioCentury’s roundup of translational news
BioCentury | Jan 21, 2022
Management Tracks
Blueprint promotes Philina Lee, expands Helen Ho’s role
Plus Clyburn leaving Merck & Co. and updates from Third Rock, BioTheryX, Ambys and more
BioCentury | Jan 13, 2022
Data Byte
Voltage-gated sodium channel blocker pipeline beyond pain
Lead candidates in Phase II testing to treat seizures and irregular heart rate
BioCentury | Aug 4, 2021
Management Tracks
Arbuckle becomes COO at Vertex
Plus: GlycoMimetics names Semerjian as King’s successor, plus updates from Pieris, Assembly and more
BioCentury | Oct 21, 2020
Deals
Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more
Scant competition ahead of BMS-MyoKardia dealAlthough negotiations drove the takeout price for MyoKardia Inc. (NASDAQ:MYOK) up to $225 per share from an initial offer of $185 by Bristol Myers Squibb
BioCentury | Apr 5, 2019
Company News
Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more
Items per page:
1 - 10 of 13